These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 26849823)

  • 21. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
    Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
    J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.
    Arosio M; Garrone S; Bruzzi P; Faglia G; Minuto F; Barreca A
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1091-8. PubMed ID: 11238491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Carpal tunnel syndrome in acromegaly--4-case report and review of literature].
    Imamura H; Isu T; Iwasaki Y; Sugimoto S; Abe H; Tashiro K
    Hokkaido Igaku Zasshi; 1989 Sep; 64(5):642-7. PubMed ID: 2591876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria.
    Hazer DB; Işık S; Berker D; Güler S; Gürlek A; Yücel T; Berker M
    J Neurosurg; 2013 Dec; 119(6):1467-77. PubMed ID: 24074496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels.
    Freda PU; Nuruzzaman AT; Reyes CM; Sundeen RE; Post KD
    J Clin Endocrinol Metab; 2004 Feb; 89(2):495-500. PubMed ID: 14764751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pain and carpal tunnel syndrome.
    Duckworth AD; Jenkins PJ; Roddam P; Watts AC; Ring D; McEachan JE
    J Hand Surg Am; 2013 Aug; 38(8):1540-6. PubMed ID: 23890497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?
    Kohler S; Tschopp O; Sze L; Neidert M; Bernays RL; Spanaus KS; Wiesli P; Schmid C
    Gen Comp Endocrinol; 2013 Jul; 188():282-7. PubMed ID: 23648743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Laboratory investigation of acromegaly: is basal or random GH > 0.4 µg/L in the presence of normal serum IGF-1 an important result?
    Rosario PW; Calsolari MR
    Arch Endocrinol Metab; 2015 Feb; 59(1):54-8. PubMed ID: 25926115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
    Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
    J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
    Marzullo P; Di Somma C; Pratt KL; Khosravi J; Diamandis A; Lombardi G; Colao A; Rosenfeld RG
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
    Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biochemical evidence supporting the Cortina criteria.
    von Werder K
    J Endocrinol Invest; 2005; 28(11 Suppl International):81-3. PubMed ID: 16625853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
    Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up.
    Dimaraki EV; Jaffe CA; DeMott-Friberg R; Chandler WF; Barkan AL
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3537-42. PubMed ID: 12161471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surgical efficacy of carpal tunnel release for carpal tunnel syndrome in acromegaly: report of four patients.
    Iwasaki N; Masuko T; Ishikawa J; Minami A
    J Hand Surg Br; 2005 Dec; 30(6):605-6. PubMed ID: 16095779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
    Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
    Bastemir M; Akin F; Yaylali GF
    Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly.
    Puder JJ; Nilavar S; Post KD; Freda PU
    J Clin Endocrinol Metab; 2005 Apr; 90(4):1972-8. PubMed ID: 15634715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.